Krill Oil attenuates doxorubicin induced cognitive impairment by inhibiting oxidative stress markers in the brains of wistar rats

 

Jalaiah M.1,2*, Jaya Sharma3, Pankaj Sharma4

1Research Scholar, Department of Pharmacology, Apex University, Jaipur - 303002, Rajasthan, India.

2Associate Professor, Department of Pharmacology,

QIS College of Pharmacy, Ongole - 523001, Andhra Pradesh, India.

3Professor and Principal, Department of Pharmacy, Apex University, Jaipur - 303002, Rajasthan, India.

4Registrar and Dean, Department of Pharmacy, Apex University, Jaipur - 303002, Rajasthan, India.

*Corresponding Author E-mail: jali.pharma@gmail.com

 

ABSTRACT:

Chemobrain is a typical adverse effect of chemotherapeutics agents that affects 15–80 percent of cancer patients. Doxorubicin, an antineoplastic drug, has been associated with severe neurotoxicity manifested as a loss in cognitive skills, most likely due to oxidative stress in brain. Krill oil (KO) is a unique, naturally occurring nutrient derived from a type of Antarctic krill, Euphausia superba that is commonly used as a dietary supplement and is well known for anti-inflammatory, hypolipidemic, anti-depressant and improvement of cognitive function, protection of neurodegeneration, neuroprotective and antioxidant qualities. The current study was aimed at evaluating krill oil's potential neuroprotection and memory improving benefits against Doxorubicin-induced cognitive and neurobiological defects. A novel object recognition task and Morris water maze test were conducted to evaluate the protective effect of krill oil against doxorubicin-induced memory deficits in rats. In female Wistar rats, cognitive impairment was produced by administering ten cycles of Doxorubicin (2.5mg/kg, intra peritoneal, once every five days). Krill oil (50mg/kg and 100mg/kg) was given orally starting one week prior to the doxorubicin treatment and continued throughout the study. Krill treatment (50mg/kg and 100mg/kg) significantly protected against Doxorubicin induced memory impairment. Co-administration of both doses of krill oil resulted in significantly lower the levels of tumour necrosis factor (TNFα), and acetyl cholinesterase activity. Furthermore, doxorubicin-induced oxidative and inflammatory insults in the frontal cortex and hippocampal areas of the brain were prevented by krill oil. In conclusion, krill oil may be a promising adjuvant treatment option for reducing adverse effects associated to doxorubicin treatment.

 

KEYWORDS: Krill oil, Chemo brain, Doxorubicin, Novel object recognition test, Morris water maze.

 

 


INTRODUCTION:

Cancer is a leading source of morbidity and mortality around the world, regardless of human development. On a daily basis, the global burden of cancer was expanding. According to GLOBOCAN 2018, there were 18.1 million new cancer cases and 9.6 million cancer deaths in 20181. The American Cancer Society predicts 1,762,450 new cancer cases and 606,880 cancer deaths in 2019.

 

 

From 1991 to 2016, the total cancer death rate decreased due to breakthroughs in cancer treatment. Breast cancer mortality rates have decreased across the board among all types of cancer. Early-stage breast and prostate cancers have near-100 percent relative survival, while in situ urinary bladder cancer has 95 percent2. Although survival rates have increased significantly, quality of life has been affected as a result of cancer therapies' unavoidable side effects3. One such adverse effect was cognitive dysfunction, which is becoming more prevalent and a serious source of concern for survivors, despite their high survival rates4. Chemobrain/Chemo fog/Mental fog is a chemotherapy-induced cognitive impairment. Chemobrain is characterised by deficiencies in episodic, visual, verbal, language, spatial, and working memory, as well as slower information processing speed5. According to many theories chemotherapy-induced cognitive dysfunction is thought to be caused by myelosuppression, reduced blood flow and metabolism, increased oxidative stress, and persistent neuro inflammation6. Most solid tumours and certain forms of leukaemia are treated with doxorubicin either single drug or along with other anti-cancer medications. Some chemotherapy medicines, such as cyclophosphamide and 5-flurouracil, can reaches to brain, while doxorubicin cannot. However, it may cause chemo brain by indirect processes, such as the release of inflammatory mediators which cross the BBB that promote neuro inflammation, eventually leading to neural cell death.7

 

It has been demonstrated that consuming n-3 polyunsaturated fatty acids (PUFAs) in diet is beneficial to general health. Polyunsaturated fatty acids (PUFA) are crucial in the prevention and treatment of inflammatory illnesses, autoimmune diseases, cardiovascular diseases, hypertension, and arthritis. Krill oil is a unique marine oil that is high in eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). These EPA and DHA play key roles in the prevention of oxidative stress in the nervous system. Earlier studies reported that krill oil has anti-inflammatory8, hypolipidemic9, anti-depressant10, and improvement of cognitive function11, protection of neurodegeneration12, neuroprotective13 and antioxidant properties14. Hence the current study was aimed to assess the potential of krill oil in doxorubicin-induced cognitive impairment in rats.

 

MATERIALS AND METHODS:

Animals:

Healthy female wistar rats of body weight 180-200g were procured from Mahaveer enterprises Hyderabad. The animal experimental protocol was authorized by institutional animal ethical committee (IAEC: 1921/PO/Re/S/16/CPCSEA) of QIS College of Pharmacy Ongole. The rats were housed in clear plastic cages with a 12-hour light/dark cycle at 23°C and were given free access to water and food on a daily basis.

 

Treatment schedule

In this study, four experimental groups each with nine animals were used. Normal saline was administered to the Groups I animals, while groups II ,III and IV received Doxorubicin 2.5mg/kg, intraperitoneal injection once every 5 days for a minimum of 10 cycles for a period of 50 days . Animals in groups III and IV were received daily doses of krill oil 50mg/kg and 100 mg/kg (p.o). The krill oil dosing were started one week before to first doxorubicin injection and continued till the completion of the experiment. Total treatment protocol was depicted in figure no 1.


 

Figure 1: Study time line of doxorubicin treatment and krill oil treatment.

 


 

Dosing of krill oil:

Krill oil which was used for this experiment was obtained from commercial available krill oil capsules of Nutricost Made in USA. Each 500mg krill oil capsule consist of omegea-3-fattyacids, DHA, EPA, phospholipids and astaxanthine. Doses of krill was calculate by converting HED (human equivalent dose) to AED (animals equivalent dose) by using conversion factor formula that is Animal dose (mg/kg) = Human dose (mg/Kg) × conversion factor15. From dosing calculation two doses 50mg/kg and 100mg/kg were used for the experiment.

 

Novel object recognition task (NORT)16:

After the completion of the Doxorubicin 10 cycle chemobrain induction period, the rats were subjected to a NORT task. The major goal of the novel object recognition test is to determine whether an animal prefers to explore a novel object over a familiar one. The present study was conducted according to a procedure by Ramalingyya et al. Square boxes with a volume of 40 cm× 40cm × 40cm made with acrylic sheet were used for the experiment. There were three steps to the test: habituation, familiarisation, and a recognition trial. On day 1, the animals were acclimated to the experimental room's surroundings, placed in square arenas, and permitted to explore the experimental set up for 20 minutes during the habituation phase. On day 2 (familiarisation trail), two identical objects were placed in square arenas and the animals were allowed to explore the objects for about 3 minutes of familiarisation time. The arena was washed with 25% ethanol to remove any odour indications before the next trial. After the 2 hours of inter-trail interval (ITI), recognition trails were conducted. Among two identical objects, one object was replaced with a novel object and the time spent by each animal in examining the familiar object and the novel object over a period of 3 min was recorded in recognition trails. A camera was set above the observation area to capture the entire experiment (Logitech Quick Cam Pro Pro9000). Recordings were analysed by using the ANY-maze video tracking system trail software (6.35 version, 1999–2021 Stoelting Co.). The recognition index (RI) and discriminative index (DI) of the animals were calculated by using the below formula

 

The recognition index (RI) = Y/(X+Y)

Discriminative index (DI) = (Y-X)

X= Time in seconds spent by animals exploring the familiar object in recognition trails

Y= Time in seconds spent by animals exploring the novel object in recognition trails

 

Morris water maze task17:

Black circular tank which was having 120cm in diameter 50cm in height was used for the study. Four distal landmarks of different shape (circular, square, triangle and diamond) and colours visual cues were provided to the animals around the tank during the training days and these cues serves as spatial cues to animals. Circular plexi glass platform 10cm in diameter 24cm in height was placed in one of the four quadrants. The plat form was kept at constant location and position during the trails. The water maze task was conducted in two phases acquisition and probe trails. In Acquisition phase each animal was underwent four successive trails per day for four days with an interval of 15 min between trails. The animals were released into the water by facing the tank wall and animals were allowed to find the hidden platform by using visual cues. The sequence of stating point was different in each day to help the rat in gaining of spatial memory of the area. The training trails were ended if the rat was reached the hidden platform and allowed the rat to stay on platform for at least 10 seconds. The animals could not found the platform with in 60 sec was placed on the platform for 10 seconds. Flag was placed on the platform to increase the visibility. The plat form location was same throughout the acquisition trails. On day 5 probe test was conducted by removing the platform in the tank, in this task animals were released into the pool and allowed the animals to reach the target quadrant where the platform was previously located. Duration spent and the frequency that entered into the target quadrant was recorded by using ANY-maze video tracking system trail software (6.35 version, 1999–2021 Stoelting Co.). After completion of task rats were dried and ensured normothermia before returning to home cage.

 

Estimation of TNF-α levels:

TNF- α levels were measured in hippocampus and frontal brain areas using an ELISA kit. Assay was done according to the instruction given by manufacturer.

 

Acetylcholinesterase activity:

The hippocampus and frontal cortex regions were isolated from the rats’ brains and homogenised using phosphate buffer (pH 7.4). The supernatants were separated for acetylcholinesterase estimation18.

 

Oxidative stress markers:

After the experimental animals were euthanized, the brains were rapidly removed and isolated the regions of the hippocampus and frontal cortex. A homogenizer (REMI) was used to homogenise the samples in phosphate buffer (0.1 M, pH 7.4). These homogenates were stored at 20°C and used to measure brain antioxidant levels. In the hippocampus and frontal cortex, levels of cellular oxidative defence such as superoxide dismutase (SOD), catalase, glutathione (GSH), and total thiols were measured19-23.

 

Statistical analysis:

Statistical analysis was done by using Graph pad statistical software trail version (9.2.0). Student's paired t-test (within the group and between the objects) was used to compare exploration time, while Kruskal–Wallis test and Dunn's post hoc test were used to compare recognition index and discriminative index in the behavioural study. Students' unpaired t-test was used to compare the group’s Morris water maze data, which included target latency, Q4 latency and Q4 time. Acetyl cholinesterase, TNF-α, and oxidative indicators were studied using one-way ANOVA, followed by Dunnett's post hoc test. P<0.05 was chosen as a statistically significant value

 

RESULTS AND DISCUSSION:

NORT Task:

In Novel object recognition test it was observed that all groups of animals spent almost exactly the same amount of time for examining two identical objects in the familiarisation trial, implying that there was no preference or discrimination toward either of the objects provided to animals. During recognition trials, normal control rats were able to recognise familiar objects and spent considerably more time with novel objects than familiar ones, indicating discrimination after a 2-hour ITI. But the Doxorubicin (DOX) treated animals has spent almost more time in examining the familiar objects than Novel object which indicates that, these animals forgot the familiar object. This representing that long term treatment with Doxorubicin (DOX) resulted in episodic memory difficulties for recognition of object which may be considered as additional complication of chemotherapy-induced neurocognitive dysfunction (chemobrain). When compared the chronic Doxorubicin received group to the normal control group, it was observed that both the discriminative and recognition indices were significantly (p<0.001) reduced in the chronic DOX group.

 

However, pretreatment with krill oil (KO) at doses of 50 mg/kg and 100mg/kg dramatically restored episodic memory deficits in a dose-dependent manner, as evidenced by a significant difference in the duration of exploration time When comparing the groups treated with krill oil (KO) to the groups treated with Doxorubicin, it was discovered that the discriminative and recognition indices were significantly enhanced in the groups treated krill oil (KO) (figure no 2). This suggests that the co-administration of krill oil with doxorubicin provided significant protection against DOX-induced chemobrain in terms of episodic memory and cognitive processing.

 


 

Figure 2: Effect of krill oil on doxorubicin induced memory impairment in rats

Note: Values were expressed mean ± SEM A. Recognition trails time spent at novel object and familiar object (*p<0.001 vs familiar object), B. Recognition index and Discriminative index (*p<0.001 vs control, #p<0.001 vs Doxorubicin control); DOX-Doxorubicin, KOLD-krill oil lower dose (50mg/kg), KOHD-krill oil higher dose (100mg/kg)

 


Morris water maze task:

On four training days, there were no significant variations in the escape latency among the six groups in the MWM task for evaluating spatial memory. On fifth day during probe trails, chronic doxorubicin treatment significantly reduced the Q4 time and increased Q4 latency as compared to normal control. This indicates that chronic treatment of Doxorubicin effects the spatial memory. Our findings are also consistent with earlier research that found DOX treatment to impair contextual and cued fear conditioning performance and spatial memory24,25. The animals treated with krill oil doses of 50mg/kg and 100mg/kg significantly increased time spent in the target quadrant (Q4 time) and reduced the time to reach the target quadrant (Q4 latency) when compared to the doxorubicin received animals (Figure no 3). This results indicating that animals treated with krill oil protected from loss of learning and memory produced by doxorubicin in animals which was consistent with earlier reports by Gamoh et al. (2011), that phospholipids in krill oil improve the spatial memory by increasing n-3 PUFA in brain.


 

 

Figure 3: Effect of krill oil on doxorubicin induced spatial acquisition learning and memory deficits in MWM test

Note: Values were expressed mean ± SEM of A. Escape latency during trail days B. Track plots C. Q4 (Target) time D. Q4 (Target latency in probe trails (*p<0.01 vs control, #p<0.001 vs Doxorubicin control); DOX-Doxorubicin, KOLD-krill oil lower dose (50mg/kg), KOHD-krill oil higher dose (100mg/kg)

 


TNF-α Levels

Doxorubicin treated animals showed elevated levels of TNF-α as compared to vehicle treated animals significantly in hippocampal and frontal cortex tissues. Chronic krill oil administration significantly reduced the doxorubicin elevated TNF-α levels in the hippocampal and frontal cortex regions of brain (Figure no 4). In previous investigations, increased tumor necrosis factor levels were seen in cancer patients after doxorubicin therapy. This represents TNF alpha-mediated inflammation caused by doxorubicin, which is a common feature of doxorubicin produced memory impairment26-29. In our current study, doxorubicin administration dramatically increased TNF-alpha levels in the hippocampal and frontal cortical areas of rats' brains, suggesting a heightened neuroinflammation. The animals which are treated with krill oil significantly reduced TNF-alpha levels indicating its anti-inflammatory effect.


 

 

Figure 4: Effect of krill oil treatment on doxorubicin induced inflammatory marker TNF-α in hippocampus and frontal cortex

Note: Values were expressed mean ± SEM of A. TNF-α levels in frontal cortex B. TNF-α levels in hippocampus (*p<0.01 vs control, #p<0.001 vs Doxorubicin control); DOX-Doxorubicin, KOLD-krill oil lower dose (50mg/kg), KOHD-krill oil higher dose (100mg/kg)


Acetylcholinesterase levels:

The hippocampus's acetylcholine levels are crucial for learning and memory. Many memory-related disorders, such as Alzheimer's and dementia, are caused by inadequate of acetylcholine in the central nervous system30,31. We investigated the impact on Acetylcholine esterase as a measure of cholinergic neurons impairment. Increased acetylcholine esterase levels were seen in the hippocampal and frontal cortex regions of doxorubicin treated rats, indicating that doxorubicin causes oxidative stress in the hippocampal and frontal cortex regions of the brain (Figure no 5). Because acetylcholine esterase inhibition is commonly used to treat cognitive deficit-related disorders, we discovered that krill oil restored acetylcholine esterase function in rats administered doxorubicin.

 

Oxidative stress markers:

To determine the impact of krill oil and Doxorubicin treatment on frontal cortex and hippocampus oxidative stress, we evaluated the concentrations of GSH, SOD, thiols, and catalase. As compared to the vehicle-treated group, Doxorubicin treatment has a considerable pro-oxidant effect, as evidenced by large significant reductions in GSH, SOD, thiols, and catalase levels. In contrast, co-treatment of krill oil with Doxorubicin significantly restored normal GSH, SOD, thiol levels, and catalase activity. As demonstrated by significant reductions in SOD, GSH, thiols, and catalase activity in the current investigation, the cognitive deficits caused by doxorubicin treatment for 50 days were connected to elevated oxidative markers in the hippocampal and frontal cortical regions of the brain. Similarly, it has been demonstrated that DOX's neurotoxic effects are related to decreased GSH, SOD, thiols, and catalase levels32,33.This demonstrates krill oil's ability to reduce oxidative stress in doxorubicin-treated rats34. The results were expressed in table no. 1 and 2.


 

Figure 5: Effect of krill oil treatment on hippocampal and frontal cortex Acetylcholineestrase activity in doxorubicin treated rats

Note: Values were expressed mean ± SEM of A. Ach esterase activity in frontal cortex B. Ach esterase activity in hippocampus (*p<0.01 vs control, #p<0.001 vs Doxorubicin control); DOX-Doxorubicin, KOLD-krill oil lower dose (50mg/kg), KOHD-krill oil higher dose (100mg/kg)

 

Table 1: Effect of krill oil treatment on oxidative stress markers in hippocampus of doxorubicin treated rats

GROUPS

GSH

(µg/mg of protein)

THIOLS

(µg/mg of protein)

SOD

(Units/mg of protein)

CATALASE

(Units/mg of protein)

CONTROL

6.81 ± 0.87

12.41 ± 0.91

14.61 ± 2.14

2.70 ± 0.22

DOX

1.91 ± 0.26*

4.50 ± 0.63*

6.43 ± 0.85*

1.01 ± 0.33*

KOLD

4.25 ± 0.72#

10.12 ± 1.48#

12.68 ± 1.51#

2.01 ± 0.35#

KOHD

5.90 ± 0.66#

11.16 ± 1.91#

13.58 ± 1.62#

2.45 ± 0.21#

Note: Values were expressed mean ± SEM (*p<0.01 vs control, #p<0.001 vs Doxorubicin control); DOX-Doxorubicin, KOLD-krill oil lower dose (50mg/kg), KOHD-krill oil higher dose (100mg/kg)

 

Table 2. Effect of krill oil treatment on oxidative stress markers in frontal cortex of doxorubicin treated rats

GROUPS

GSH

(µg/mg of protein)

THIOLS

 (µg/mg of protein)

SOD

(Units/mg of protein)

CATALASE

(Units/mg of protein)

CONTROL

5.61 ± 0.71

11.62 ± 0.87

13.42 ± 1.24

 3.69 ± 0.42

DOX

1.28 ± 0.16*

3.80 ± 0.44*

4.56 ± 0.75*

 1.15 ± 0.41*

KOLD

3.75 ± 0.12#

8.99 ± 1.26#

10.78 ± 1.44#

2.81. ± 0.48#

KOHD

4.29 ± 0.16#

9.85 ± 1.83#

12.16 ± 1.32#

2.95 ± 0.21#

Note: Values were expressed mean ± SEM (*p<0.01 vs control, #p<0.001 vs Doxorubicin control); DOX-Doxorubicin, KOLD-krill oil lower dose (50mg/kg), KOHD-krill oil higher dose (100mg/kg)

 


CONCLUSION:

The rats were protected from DOX-induced chemobrain for both episodic and spatial components when they were treated with krill oil. Krill oil enhanced cognitive performance in rats by reducing oxidative damage in the brain. The current study suggests that naturally occurring krill oil could be a beneficial anti-amnestic and neuroprotective treatment for doxorubicin-induced cognitive impairments. Furthermore, the current study stimulates further clinical research into the neuronal protective advantages of krill oil intake in cancer patients receiving doxorubicin.

 

CONFLICT OF INTEREST:

There is no conflict of interest

 

REFERENCES:

1.     Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., and Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018; 68(6): 394-424. doi.org/10.3322/ caac.21492.

2.     Siegel, R. L., Miller, K. D., and Jemal, A. Cancer statistics, 2019. CA: a cancer journal for clinicians. 2019; 69(1): 7-34. doi.org/10.3322/ caac.21565.

3.     Ahles, T. A., and Saykin, A. J. Breast cancer chemotherapy-related cognitive dysfunction. Clinical breast cancer. 2002; 3(3): S84-S90. doi.org/ 10.3816/CBC.2002.s.018

4.     Nelson, C. J., Nandy, N., and Roth, A. J. Chemotherapy and cognitive deficits: mechanisms, findings, and potential interventions. Palliative and supportive care. 2007; 5(3): 273-280. doi.org/10.1017/S1478951507000442

5.     Bender, C. M., Sereika, S. M., Berga, S. L., Vogel, V. G., Brufsky, A. M., Paraska, K. K., and Ryan, C. M. Cognitive impairment associated with adjuvant therapy in breast cancer. PsychoOncology. Journal of the Psychological, Social and Behavioral Dimensions of Cancer. 2006; 15(5): 422-430. doi.org/ 10.1002/pon.964

6.     Myers, J. S. The possible role of cytokines in chemotherapy-induced cognitive deficits. In Chemo Fog. 2010; (pp. 119-123): Springer, New York, NY.doi.org/ 10.1007/978-1-4419-6306-2_15

7.     Singal, P., Li, T., Kumar, D., Danelisen, I., and Iliskovic, N. Adriamycin-induced heart failure: mechanisms and modulation. Molecular and cellular biochemistry. 2000; 207(1-2): 77-86. doi.org/10.1023/A:1007094214460

8.     Kim, H. D., Lee, S. B., Ko, S. C., Jung, W. K., Kim, Y. M., and Kim, S. B. Anti-inflammatory effect of ozonated krill (Euphausia superba) oil in lipopolysaccharide-stimulated RAW 264.7 macrophages. Fisheries and Aquatic Sciences. 2018; 21(1): 15. doi.org/10.1186/s41240-018-0092-1

9.     Cicero, A. F., Rosticci, M., Morbini, M., Cagnati, M., Grandi, E., Parini, A., and Borghi, C. Lipid-lowering and anti-inflammatory effects of omega 3 ethyl esters and krill oil: a randomized, cross-over, clinical trial. Archives of medical science: AMS. 2016; 12(3): 507. doi: 10.5114/aoms.2016.59923

10.   Wibrand, K., Berge, K., Messaoudi, M., Duffaud, A., Panja, D., Bramham, C. R., and Burri, L. Enhanced cognitive function and antidepressant-like effects after krill oil supplementation in rats. Lipids in health and disease. 2013; 12(1): 6. doi.org/10.1186/ 1476-511X-12-6

11.   Burri, L. Krill oil supplementation and cognitive function. In Diet and Nutrition in Dementia and Cognitive Decline. 2015 Jan 1; (pp. 1031-1038). Academic Press. doi.org/10.1016/B978-0-12-407824-6.00096-3

12.   Mansour, S. Z., Moustafa, E. M., Hassan, A. A., and Thabet, N. M. Protective role of Krill oil against estrogen deficiency induced neurodegeneration in ovariectomized rats. Indian journal of experimental biology. 2017; 55: 279285. doi.org/nopr.niscair.res.in/handle/123456789/ 41727

13.   Jayanth P. C., Prasanna Kumar Kar, M. Niranjan Babu. Evaluation of Nootropic activity Potential of Krill Oil in Diazepam Induced Amnesic Mice. Research Journal of Pharmacology and Pharmacodynamics.2016; 8(3): 111-114.. doi: 10.5958/2321-5836.2016.00020.3

14.   Li, Q., Wu, F., Wen, M., Yanagita, T., Xue, C., Zhang, T., and Wang, Y. The Protective Effect of Antarctic Krill Oil on Cognitive Function by Inhibiting Oxidative Stress in the Brain of Senescence Accelerated Prone Mouse Strain 8 (SAMP8) Mice. Journal of food science. 2018; 83(2): 543-551. doi.org/10.1111/ 1750-3841.14044

15.   Shin, J. W., Seol, I. C., and Son, C. G. Interpretation of animal dose and human equivalent dose for drug development. The Journal of Korean Medicine. 2010; 31(3): 1-7. doi/koreascience.or.kr/article/ JAKO201025665646491

16.   Ramalingayya, G. V., Cheruku, S. P., Nayak, P. G., Kishore, A., Shenoy, R., Rao, C. M., and Krishnadas, N. Rutin protects against neuronal damage in vitro and ameliorates doxorubicin-induced memory deficits in vivo in Wistar rats. Drug design, development and therapy. 2017; 11: 1011. doi: 10.2147/DDDT.S103511

17.   Nagaraju B, Chandrasekhar K, Uma Sankar G, GSN Koteswarao, Umasankar K, A. Ankarao..Neuroprotective effect of Conessinin on Elevated oxidative stress induced Alzheimers’disease in rats. Research Journal of Pharmacy and Technology. 2020; 13(6): 2703-2707. doi: 10.5958/0974-360X.2020.00481.3

18.   Vaishali J. Mahadik, Monika N. Chavare, S. S. Patil, Kiran A. Wadkar. Cognition Enhancing potential of Sesbania grandiflora fruit extract in Scopolamine induced Amnesia in mice. Research Journal of Pharmacy and Technology. 2020; 13(11): 5057-5062. doi: 10.5958/0974-360X.2020.00886.0

19.   Moron MS, Depierre JW, Mannervik B. Levels of glutathione, gluta thione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys Acta. 1979; 582(1): 67–78. doi.org/10.1016/0304-4165(79)90289-7

20.   Misra HP, Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. Journal of Bio Chemistry. 1972; 247(10): 3170–3175. doi.org/10.1016/S0021-9258(19)45228-9

21.   Aebi H. Catalase. Methods in Enzymatic Analysis. New York, NY: Academic Press; 1974: 673–678. doi.org/10.1016/b978-0-12-091302-2.50032-3

22.   Pragati Khare, Kamal Kishore, Dinesh Kumar Sharma. Catalase and Superoxide Dismutase (SOD) activity in Swiss Albino mice treated with Ethanolic leaf extract of Bauhinia variegata. Research Journal of Pharmacy and Technology. 2019; 12(9): 4259-4262. doi:10.5958/0974-360X.2019.00732.7

23.   Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Analytical Biochemistry. 1968; 25(1): 192–205. DOI: 10.1016/ 0003-2697(68)90092-4

24.   Christie LA, Acharya MM, Parihar VK, Nguyen A, Martirosian V, Limoli CL .Impaired cognitive function and hippocampal neurogenesis following cancer chemotherapy. Clinical Cancer Research. 2012; 18(7): 1954–1965. doi.org/10.1158/1078-0432.CCR-11- 2000

25.   Kitamura Y, Hattori S, Yoneda S et al. Doxorubicin and cyclophosphamide treatment produces anxiety-like behavior and spatial cognition impairment in rats: possible involvement of hippocampal neurogenesis via brain-derived neurotrophic factor and cyclin D1 regulation. Behavarial Brain Research. 2015; 292: 184–193. doi. org/10.1016/j.bbr.2015.06.007

26.   Hayslip J, Dressler EV, Weiss H et al. Plasma TNF-α and soluble TNF receptor levels after doxorubicin with or without coadministration of mesna—a randomized, cross-over clinical study. PLoS One. 2015 Apr 2014; 10(4): 1–14. doi.org/10.1371/ journal.pone. 0124988

27.   Aluise CD, Sultana R, Tangpong J et al .Chemo brain (chemo fog) as a potential side effect of doxorubicin administration: role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction. Advances in Experimental Medical Biology. 2010; 147–156: doi.org/10.1007/978-1-4419-6306-2_19

28.   Keeney J. Doxorubicin-induced, TNF-α-mediated brain oxidative stress, neurochemical alterations, and cognitive decline: insights into mechanisms of chemotherapy induced cognitive impairment and its prevention. Theses and Dissertations--Chemistry. 2013. doi.uknowledge.uky.edu/ chemistry_etds/27

29.   Mohamed H. Sherif, Al-Shimaa M. Abas, Lobna A. Zaitoun. Ginger extract protect Iodinated Contrast Media Nephrotoxicity in rats through modulation of Oxidative Stress, Cystain C, NGAL and TNF α. Research Journal of Pharmacy and Technology 2018; 11(12): 5439-5448. doi: 10.5958/0974-360X.2018.00992.7

30.   Yamana Srikanth, T Tamilanban, V Chitra. Medicinal plants Targeting Alzheimer’s disease - A Review. Research Journal of Pharmacy and Technology. 2020; 13(7): 3454-3458. doi:10.5958/0974-360X.2020.00613.7

31.   Rahul P. Jadhav, Manohar D. Kengar, Omkar V. Narule, Vikranti W. Koli, Suraj B. Kumbhar. A Review on Alzheimer’s Disease (AD) and its Herbal Treatment of Alzheimer’s Disease. Asian Journal of Research in Pharmaceutical Sciences. 2019; 9(2): 112-122. doi: 10.5958/2231-5659.2019.00017.1

32.   Joshi G, Sultana R, Tangpong J et al. Free radical mediated oxidative stress and toxic side effects in brain induced by the anti-cancer drug adriamycin: insight into chemobrain. Free Radical Research. 2005; 39(11): 1147–1154. doi.org/10.1080/ 10715760500143478

33.   Shyamala Nayak, Nayanatara Arun Kumar, Anupama Hegde, Rekha D Kini, Vandana Blossom, Roopesh Poojary. Neuroprotective role of Allium cepa and Allium sativum on Hippocampus, striatum and Cerebral cortex in Wistar rats. Research Journal of Pharmacy and Technology. 2021; 14(5): 2406-1. doi: 10.52711/0974-360X.2021.00424

34.   Dose J, Matsugo S, Yokokawa H et al (2016) Free radical scavenging and cellular antioxidant properties of astaxanthin. International Journal of Molecular Science. 2016; 17(1). doi.org/10.3390/ijms17010103

 

 

 

 

 

Received on 23.11.2021          Modified on 26.02.2022

Accepted on 03.05.2022        © RJPT All right reserved

Research J. Pharm. and Tech 2023; 16(2):652-658.

DOI: 10.52711/0974-360X.2023.00111